4579.T
RaQualia Pharma Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 550.00
+0.92%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.8B | 4.0B | 3.1B | 1.9B | 2.9B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | — | — | — | — | — |
| Cost and Expenses | 3.6B | 3.5B | 3.3B | 2.2B | 2.1B |
| Operating Income (EBIT) | 230.0M | 483.0M | (213.0M) | (337.0M) | 866.0M |
| Non-Operating | |||||
| Interest Income | 20.7M | 17.4M | 5.3M | 3.4M | 529.0K |
| Interest Expense | 59.7M | 59.1M | 42.6M | 6.7M | 6.0M |
| Net Interest Income | (39.0M) | (41.6M) | (37.3M) | (3.3M) | (5.5M) |
| Other Non-Op Income/Expense | 19.6M | (45.8M) | (148.1M) | 44.0M | 38.1M |
| Non-Operating Income (excl Interest) | 62.4M | 52.5M | 62.4M | 84.8M | 76.1M |
| EBT (Pre-Tax Income) | 250.0M | 437.9M | (357.7M) | (294.0M) | 851.0M |
| Income Tax Expense | 197.4M | 164.8M | 137.3M | 29.6M | 127.6M |
| Bottom Line | |||||
| Net Income | 53.0M | 273.0M | (495.0M) | (323.0M) | 723.0M |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 53.0M | 273.0M | (495.0M) | (323.0M) | 723.0M |
| Per Share | |||||
| Basic EPS | ¥2 | ¥12 | (¥23) | (¥15) | ¥35 |
| Diluted EPS | ¥2 | ¥11 | — | — | ¥34 |
| Revenue Per Share | ¥149 | ¥168 | ¥144 | ¥88 | ¥139 |
| Shares | |||||
| Basic Shares Outstanding | 25.5M | 23.7M | 21.6M | 21.6M | 21.0M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | 427.1M | 685.9M | (14.8M) | (161.4M) | 1.0B |
| D&A | 197.1M | 202.9M | 198.2M | 175.6M | 147.7M |
| EBIT | 230.0M | 483.0M | (213.0M) | (337.0M) | 866.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026